Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Research Article

Metabolic Imbalance and Vitamin D Deficiency in Type 1 Diabetes in the Algerian Population

Author(s): Esma Mihoubi, Rachida Raache*, Habiba Amroun, Malha Azzouz, Assia Galleze, Nesrine Zaabat, Abdelghani Aissou, Amina Ferhat, Hassiba Guettaf-Sadi, Amel Boutemeur, Zoulikha Aoudia, Aissa Boudiba, Chafia Touil-Boukoffa, Mohamed C. Abbadi and Nabila Attal

Volume 19, Issue 8, 2019

Page: [1172 - 1176] Pages: 5

DOI: 10.2174/1871530319666190529113404

Price: $65

Abstract

Background: We aimed to assess Vitamin D levels in patients with Type 1 Diabetes (T1D) and to investigate the correlation between vitamin D and metabolic imbalance.

Material and Methods: For our study, we selected thirty-one patients with T1D without complications and fifty-seven healthy controls. Diabetic patients were diagnosed using the criteria of the World Health Organization/American Diabetes Association. Vitamin D, Parathyroid Hormone (PTH), insulin and C peptide assay were performed using chimilunescence. Glucose level, lipid profile, glycated haemoglobin (HbA1c) and ionogram were also analysed.

Results: Vitamin D, HbA1c and Gly levels were found to be significant in T1D patients than in controls (P<0.5). However, for PTH, no significant difference was observed (P > 0. 05) and the results show a non-significant difference of total cholesterol potassium, sodium, phosphor and calcium concentration averages.

Conclusion: Our results indicate that the deficiency of VD is associated with an increased risk of T1DM in Algerian population.

Keywords: Diabetes Type 1 (DT1), Parathyroid Hormone (PTH), Vitamin D, glycemic level, modulation, HbA1c.

Graphical Abstract

[1]
Wall, J.R.; Lahooti, H. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases? Endokrynol. Pol., 2010, 61(2), 222-227.
[PMID: 20464711]
[2]
Perros, P.; Neoh, C.; Dickinson, J. Thyroid eye disease. BMJ, 2009, 338, b560.
[http://dx.doi.org/10.1136/bmj.b560] [PMID: 19270020]
[3]
Phelps, P.O.; Williams, K. Thyroid eye disease for the primary care physician. Dis. Mon., 2014, 60(6), 292-298.
[http://dx.doi.org/10.1016/j.disamonth.2014.03.010] [PMID: 24906675]
[4]
Wu, S.; Cai, T.; Chen, F.; He, X.; Cui, Z. Genetic associations of FCRL3 polymorphisms with the susceptibility of Graves ophthalmopathy in a Chinese population. Int. J. Clin. Exp. Med., 2015, 8(9), 16948-16954.
[PMID: 26629249]
[5]
Xiao, L.; Muhali, F.S.; Cai, T.T.; Song, R.H.; Hu, R.; Shi, X.H.; Jiang, W.J.; Li, D.F.; He, S.T.; Xu, J.; Zhang, J.A. Association of single-nucleotide polymorphisms in the STAT3 gene with autoimmune thyroid disease in Chinese individuals. Funct. Integr. Genomics, 2013, 13(4), 455-461.
[http://dx.doi.org/10.1007/s10142-013-0337-0] [PMID: 24081513]
[6]
Song, R.H.; Li, Q.; Wang, W.; Yao, Q.M.; Shao, X.Q.; Zhang, J.A. Variants of Interleukin-22 Gene Confer Predisposition to Autoimmune Thyroid Disease. Int. J. Endocrinol., 2017.20173428236
[http://dx.doi.org/10.1155/2017/3428236] [PMID: 28839453]
[7]
Weiler, D.L. Thyroid eye disease: a review. Clin. Exp. Optom., 2017, 100(1), 20-25.
[http://dx.doi.org/10.1111/cxo.12472] [PMID: 27701774]
[8]
Melcescu, E.; Horton, W.B.; Kim, D.; Vijayakumar, V.; Corbett, J.J.; Crowder, K.W.; Pitman, K.T.; Uwaifo, G.I.; Koch, C.A. Graves orbitopathy: update on diagnosis and therapy. South. Med. J., 2014, 107(1), 34-43.
[http://dx.doi.org/10.1097/SMJ.0000000000000038] [PMID: 24389785]
[9]
Huang, D.; Xu, N.; Song, Y.; Wang, P.; Yang, H. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy. Graefes Arch. Clin. Exp. Ophthalmol., 2012, 250(4), 619-625.
[http://dx.doi.org/10.1007/s00417-011-1863-x] [PMID: 22124787]
[10]
Shen, J.; Li, Z.; Li, W.; Ge, Y.; Xie, M.; Lv, M.; Fan, Y.; Chen, Z.; Zhao, D.; Han, Y. Th1, Th2, and Th17 Cytokine Involvement in Thyroid Associated Ophthalmopathy. Dis. Markers, 2015.2015609593
[http://dx.doi.org/10.1155/2015/609593] [PMID: 26089587]
[11]
Barrio-Barrio, J.; Sabater, A.L.; Bonet-Farriol, E.; Velázquez-Villoria, Á.; Galofré, J.C. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J. Ophthalmol., 2015.2015249125
[http://dx.doi.org/10.1155/2015/249125] [PMID: 26351570]
[12]
Bartalena, L.; Baldeschi, L.; Dickinson, A.J.; Eckstein, A.; Kendall-Taylor, P.; Marcocci, C.; Mourits, M.P.; Perros, P.; Boboridis, K.; Boschi, A.; Currò, N.; Daumerie, C.; Kahaly, G.J.; Krassas, G.; Lane, C.M.; Lazarus, J.H.; Marinò, M.; Nardi, M.; Neoh, C.; Orgiazzi, J.; Pearce, S.; Pinchera, A.; Pitz, S.; Salvi, M.; Sivelli, P.; Stahl, M.; von Arx, G.; Wiersinga, W.M. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid, 2008, 18(3), 333-346.
[http://dx.doi.org/10.1089/thy.2007.0315] [PMID: 18341379]
[13]
Okrojek, R.; Grus, F.H.; Matheis, N.; Kahaly, G.J. Proteomics in autoimmune thyroid eye disease. Horm. Metab. Res., 2009, 41(6), 465-470.
[http://dx.doi.org/10.1055/s-0029-1214413] [PMID: 19373747]
[14]
Gianoukakis, A.G.; Khadavi, N.; Smith, T.J. Cytokines, Graves’ disease, and thyroid-associated ophthalmopathy. Thyroid, 2008, 18(9), 953-958.
[http://dx.doi.org/10.1089/thy.2007.0405] [PMID: 18713026]
[15]
Wakelkamp, I.M.; Bakker, O.; Baldeschi, L.; Wiersinga, W.M.; Prummel, M.F. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin. Endocrinol. (Oxf.), 2003, 58(3), 280-287.
[http://dx.doi.org/10.1046/j.1365-2265.2003.01708.x] [PMID: 12608932]
[16]
Pawlowski, P.; Wawrusiewicz-Kurylonek, N.; Eckstein, A.; Reszec, J.; Luczynski, W.; Johnson, K.; Kretowski, A.; Bakunowicz-Lazarczyk, A.; Gorska, M.; Szamatowicz, J.; Chyczewski, L.; Mysliwiec, J. Disturbances of modulating molecules (FOXP3, CTLA-4/CD28/B7, and CD40/CD40L) mRNA expressions in the orbital tissue from patients with severe graves’ ophthalmopathy. Mediators Inflamm., 2015.2015340934
[http://dx.doi.org/10.1155/2015/340934] [PMID: 25653477]
[17]
Myśliwiec, J.; Waligórski, D.; Nikołajuk, A.; Górska, M. Soluble CD40 and its ligand CD154 in patients with Graves’ ophthalmopathy during combined therapy with corticosteroids and teleradiotherapy. Adv. Med. Sci., 2007, 52, 104-108.
[PMID: 18217399]
[18]
Wakelkamp, I.M.; Gerding, M.N.; Van Der Meer, J.W.; Prummel, M.F.; Wiersinga, W.M. Both Th1- and Th2-derived cytokines in serum are elevated in Graves’ ophthalmopathy. Clin. Exp. Immunol., 2000, 121(3), 453-457.
[http://dx.doi.org/10.1046/j.1365-2249.2000.01335.x] [PMID: 10971510]
[19]
Kumar, S.; Bahn, R.S. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves’ ophthalmopathy. J. Clin. Endocrinol. Metab., 2003, 88(9), 4246-4250.
[http://dx.doi.org/10.1210/jc.2003-030380] [PMID: 12970294]
[20]
Lv, M.; Shen, J.; Li, Z.; Zhao, D.; Chen, Z.; Wan, H.; Hao, B. [Role of Treg/Th17 cells and related cytokines in Graves’ ophthalmopathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014, 34(12), 1809-1813. [Role of Treg/Th17 cells and related cytokines in Graves’ ophthalmopathy
[PMID: 25537908]
[21]
Ujhelyi, B.; Gogolak, P.; Erdei, A.; Nagy, V.; Balazs, E.; Rajnavolgyi, E.; Berta, A.; Nagy, E.V. Graves’ orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Thyroid, 2012, 22(4), 407-414.
[http://dx.doi.org/10.1089/thy.2011.0248] [PMID: 22385289]
[22]
Jia, H.Y.; Zhang, Z.G.; Gu, X.J.; Guo, T.; Cui, B.; Ning, G.; Zhao, Y.J. Association between interleukin 21 and Graves’ disease. Genet. Mol. Res., 2011, 10(4), 3338-3346.
[http://dx.doi.org/10.4238/2011.October.31.6] [PMID: 22057994]
[23]
Li, C.; Yuan, J.; Zhu, Y.F.; Yang, X.J.; Wang, Q.; Xu, J.; He, S.T.; Zhang, J.A. Imbalance of Th17/Treg in Different Subtypes of Autoimmune Thyroid Diseases. Cell. Physiol. Biochem., 2016, 40(1-2), 245-252.
[http://dx.doi.org/10.1159/000452541] [PMID: 27855396]
[24]
Fang, S.; Huang, Y.; Zhong, S.; Zhang, Y.; Liu, X.; Wang, Y.; Gu, P.; Zhou, H.; Fan, X. IL-17A Promotes RANTES Expression, But Not IL-16, in Orbital Fibroblasts Via CD40-CD40L Combination in Thyroid-Associated Ophthalmopathy. Invest. Ophthalmol. Vis. Sci., 2016, 57(14), 6123-6133.
[http://dx.doi.org/10.1167/iovs.16-20199] [PMID: 27832278]
[25]
Fang, S.; Huang, Y.; Zhong, S.; Li, Y.; Zhang, Y.; Li, Y.; Sun, J.; Liu, X.; Wang, Y.; Zhang, S.; Xu, T.; Sun, X.; Gu, P.; Li, D.; Zhou, H.; Li, B.; Fan, X. Regulation of Orbital Fibrosis and Adipogenesis by Pathogenic Th17 Cells in Graves Orbitopathy. J. Clin. Endocrinol. Metab., 2017, 102(11), 4273-4283.
[http://dx.doi.org/10.1210/jc.2017-01349] [PMID: 28938397]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy